Asked by: Shivani Raja (Conservative - Leicester East)
Question to the Department for Science, Innovation & Technology:
To ask the Secretary of State for Science, Innovation and Technology, what steps her Department is taking to ensure that (a) Leicester and (b) the East Midlands benefit from national investment in emerging technologies, including artificial intelligence and advanced manufacturing.
Answered by Kanishka Narayan - Parliamentary Under Secretary of State (Department for Science, Innovation and Technology)
The Government is putting technology at the heart of our mission to grow the UK economy.
We are launching a £250 million procurement to expand the AI Research Resource, giving UK researchers and businesses free access to cutting‑edge compute so every region can benefit from nationwide innovation.
The Government is also expanding access to free AI skills training, available to all adults across the UK, that aims to equip 10 million workers with practical AI skills by 2030, ensuring people and businesses in every region can take advantage of new technologies.
Alone, Leicester City Council received £35,391.97 from the Digital Inclusion Innovation Fund for its ‘Let’s Get Digital’ project, which will help 150 peoples, this will build digital confidence for social inclusion, reducing service dependency and improving economic outcomes.
The Government is also supporting UK medicine and med‑tech manufacturing through the £520 million Life Sciences Innovative Manufacturing Fund, bringing high‑value jobs to regions like the East Midlands, strengthening supply chains, and securing over £30 million of new investment.
Asked by: Andrew Mitchell (Conservative - Sutton Coldfield)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to help improve the availability of clinical trials for dementia patients.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
Government responsibility for delivering dementia research is shared between the Department of Health and Social Care (DHSC), with research delivered via the National Institute for Health and Care Research (NIHR), and the Department for Science, Innovation and Technology, with research delivered via UK Research and Innovation.
DHSC is committed to ensuring that all patients, including those with dementia, have access to cutting-edge clinical trials and innovative, lifesaving treatments.
DHSC funds research and research infrastructure through the NIHR which supports National Health Service patients, the public, and NHS organisations across England to participate in high-quality research, including clinical trials into dementia
As an example, DHSC, via the NIHR, is investing nearly £50 million into the Dementia Trials Network, a coordinated network of trial sites across the United Kingdom, which will offer people with dementia the opportunity to take part in early phase clinical trials irrespective of where they live. This is complemented by the £20 million Dementia Trials Accelerator, designed to position the United Kingdom as the destination of choice for late phase clinical trials in dementia and neurodegenerative diseases.
The NIHR also funds research infrastructure which supports patients and the public to participate in high-quality research, including research on dementia. For example, the aim of the University College London Hospitals’ Biomedical Research Centre’s dementia theme is to develop novel treatments through precision medicine.
In partnership with Alzheimer’s Society, Alzheimer’s Research UK, and Alzheimer Scotland, the NIHR also delivers Join Dementia Research, an online platform which enables the involvement of people with and without a dementia diagnosis, as well as carers, to take part in a range of important research, including studies evaluating potential treatments for dementia.
The NIHR also provides an online service called 'Be Part of Research', which promotes participation in health and social care research by allowing users to search for relevant studies, including those with dementia, and register their interest.
The Government’s Dame Barbara Windsor Dementia Goals programme, with up to £150 million expected to be allocated to, or aligned with it, aims to speed up the development of new treatments for dementia and neurodegenerative conditions by accelerating innovations in biomarkers, clinical trials, and implementation.
Asked by: Lord Freyberg (Crossbench - Excepted Hereditary)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what assessment they have made of the importance of prompt, large-scale molecular testing to the efficiency of commercial clinical trial recruitment, particularly in cancer; and of how prompt, large-scale molecular testing influences industry decisions on country prioritisation and site selection, in particular for late-phase trials conducted in England.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
As set out in the Life Sciences Sector Plan, the Government aims to double commercial interventional trial participants by 2026, and again by 2029.
Access to large-scale molecular testing will play a role in delivering against this aim, since molecular testing can identify patients with specific biomarkers and target them into clinical trials. More consistent and equitable genomic testing across England will encourage commercial sponsors to place their clinical trials at research sites in the United Kingdom.
To deliver this, we are embedding genomic testing as routine practice within the NHS Genomic Medicine Service and its workforce. This includes seven NHS Genomic Laboratory Hubs delivering comprehensive genomic testing and analysis, such as whole genome sequencing, as part of routine care. The Genomics Education Programme is responsible for upskilling the entire multi-professional, multi-specialty National Health Service workforce in genomics.
The Government also supports the Rare Cancers Private Members Bill. The bill will make it easier for clinical trials on brain cancer to take place in England, by ensuring that the patient population can be more easily contacted by researchers.
Asked by: Kevin Bonavia (Labour - Stevenage)
Question to the Ministry of Defence:
To ask the Secretary of State for Defence, what assessment he has made of the adequacy of military hospital provision.
Answered by Louise Sandher-Jones - Parliamentary Under-Secretary (Ministry of Defence)
Armed Forces personnel in the UK routinely receive secondary care, including specialist hospital treatment, through the NHS, working with the Defence Medical Services (DMS) to ensure that specific defence requirements are met.
The Royal Centre for Defence Medicine is the UK's primary military medical facility. Based at the Queen Elizabeth Hospital Birmingham, military medical personnel are integrated with NHS staff to provide specialist treatment for injured military personnel, including those evacuated from overseas. It further serves as a centre for training and research.
Additionally, there are over 1000 military Doctors, Nurses and Allied Health Professionals permanently based in 56 NHS trusts across the UK, ensuring military medics maintain the skills they require to support military operations across the globe and providing essential support to our NHS. Through this partnership, Defence is supporting the government’s mission to build an NHS fit for the future with military healthcare professionals routinely treating members of the general public, however, for security reasons they are not always identifiable as being serving members of the Armed Forces.
DMS is working closely with NHS England and health services in the Devolved Administrations to ensure non-deployable personnel awaiting NHS treatment are returned to fighting fitness. Further, the Ministry of Defence (MOD) is working with the Department of Health and Social Care (DHSC) to meet the Strategic Defence Review (SDR) recommendations including rebuilding capacity and capability, in partnership with the NHS, to meet the demands of warfighting.
Asked by: Lord Kamall (Conservative - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what assessment they have made of the report Closing the Gap: A roadmap for equitable access to genomic testing and precision medical trials for all patients with a brain tumour in the UK published by the Tessa Jowell Brain Cancer Mission in September 2024.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
As part of the National Cancer Plan, officials have engaged with a range of stakeholders, including brain cancer clinical experts and charities, as well as receiving this report. The Department received over 11,000 responses to the Call for Evidence, which have been analysed to support the development the plan.
On 24 October 2025, NHS England published the Medium-Term Planning Framework – delivering change together 2026/27 to 2028/29. This sets out that all National Health Service providers must support embedding research as part of everyday care, meet the site-specific timeframes of the Government’s 150-day clinical trial set-up target, and for research activity and income to be reported to boards on a six-monthly basis.
We are also embedding genomic testing as routine practice within the NHS Genomic Medicine Service and its workforce. This includes seven NHS Genomic Laboratory Hubs delivering comprehensive genomic testing and analysis, such as whole genome sequencing, as part of routine care. The Genomics Education Programme is responsible for upskilling the entire multi-professional, multi-specialty NHS workforce in genomics.
The Government also supports the Rare Cancers Private Members Bill. The bill will make it easier for clinical trials on brain cancer to take place in England, by ensuring the patient population can be more easily contacted by researchers.
Asked by: Lord Wigley (Plaid Cymru - Life peer)
Question to the Department for Energy Security & Net Zero:
To ask His Majesty's Government whether they plan to designate the Trawsfynydd nuclear power station site as a nuclear research site for developing and producing radioisotopes for medical purposes.
Answered by Lord Vallance of Balham - Minister of State (Department for Energy Security and Net Zero)
The Nuclear Decommissioning Authority (NDA) through Nuclear Restoration Services, are decommissioning the legacy facility and own the land at Trawsfynydd. The NDA engages parties to explore maximising national and local value with the land that it owns.
The responsibility for the supply of medical radioisotopes sites with the Department of Health and Social Care. The Department for Energy Security and Net Zero provides support to other government department’s exploring nuclear medicine projects.
Asked by: Roz Savage (Liberal Democrat - South Cotswolds)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether he has made an assessment of the potential impact of the closure of specialist Long Covid clinics on the collection of data on the long-term health impacts of Covid-19; and what steps he is taking to ensure that these conditions are not under-recognised or under-resourced as a result.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
While no central assessment has been made of the impact of local closures of post-COVID-19 services on patient outcomes and data collection, the Government understands the scale of the issue at hand, particularly the impact of long COVID-19 on health, employment, and the economy.
The Government is aware that post-acute infection conditions, such as long COVID-19, can have a devastating effect on those who suffer from them. We are committed to taking a comprehensive and compassionate approach to supporting individuals with post-acute infection conditions such as long COVID-19, recognising the unique challenges these conditions present.
Integrated care boards are responsible for commissioning specialist services for long COVID-19 that meet the needs of their population, subject to local prioritisation and funding. NHS England has published commissioning guidance for post-COVID-19, or long COVID-19, services, which sets out a blueprint for best practice in supporting people with long COVID-19 and is designed to be adapted to local needs. This guidance is avaiable at the following link:
https://www.england.nhs.uk/publication/national-commissioning-guidance-for-post-covid-services/
Anyone who is concerned about long lasting symptoms after having COVID-19 should contact their general practitioner (GP). If appropriate, their GP will refer them to a National Health Service long COVID-19 service where available, or a suitable alternative, which will assess people and direct them into care pathways which provide appropriate support, treatment, and rehabilitation.
To support clinical leadership in this area, NHS England worked in partnership with the British Society of Physical and Rehabilitation Medicine to establish the International Post- Covid and Post-Infection Conditions Society to facilitate the ongoing sharing of best practice to support people affected by long COVID-19.
Ongoing projects funded through the National Institute of Health and Care Research (NIHR) and Medical Research Council (MRC) aim to improve our understanding of the diagnosis and underlying mechanisms of long COVID-19 and the effectiveness of both pharmacological and non-pharmacological therapies and interventions, as well as to evaluate clinical care. The NIHR welcomes funding applications for research into any aspect of human health, including long COVID-19. The NIHR and MRC remain committed to funding high-quality research to understand the causes, consequences, and treatment of post-viral conditions, including long COVID-19, and are actively exploring next steps for research into post-viral conditions.
On 6 November 2025, the NIHR and MRC hosted a showcase event for post-acute infection conditions, including long COVID-19, research. This brought together people with lived experience, researchers, clinicians, and research funders to help stimulate further research in this field. We are now considering discussions from the showcase event to explore next steps to stimulate further vital research in this area.
We are determined to accelerate progress in the treatment and management of long COVID-19. This includes a new funding opportunity for a development award which is focussed on the feasibility of a phase 2 platform clinical trial that tests multiple repurposed pharmaceutical interventions and/or non-pharmacological interventions and devices. This targeted funding opportunity is one component of our approach to improve evidence around the diagnosis, management, and treatment of post-acute infection conditions, including long COVID-19.
Asked by: Roz Savage (Liberal Democrat - South Cotswolds)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what data his Department holds on patient outcomes for those with Long-Covid following the closure of dedicated services; and how many former Long Covid patients are being supported through ME/CFS services.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
While no central assessment has been made of the impact of local closures of post-COVID-19 services on patient outcomes and data collection, the Government understands the scale of the issue at hand, particularly the impact of long COVID-19 on health, employment, and the economy.
The Government is aware that post-acute infection conditions, such as long COVID-19, can have a devastating effect on those who suffer from them. We are committed to taking a comprehensive and compassionate approach to supporting individuals with post-acute infection conditions such as long COVID-19, recognising the unique challenges these conditions present.
Integrated care boards are responsible for commissioning specialist services for long COVID-19 that meet the needs of their population, subject to local prioritisation and funding. NHS England has published commissioning guidance for post-COVID-19, or long COVID-19, services, which sets out a blueprint for best practice in supporting people with long COVID-19 and is designed to be adapted to local needs. This guidance is avaiable at the following link:
https://www.england.nhs.uk/publication/national-commissioning-guidance-for-post-covid-services/
Anyone who is concerned about long lasting symptoms after having COVID-19 should contact their general practitioner (GP). If appropriate, their GP will refer them to a National Health Service long COVID-19 service where available, or a suitable alternative, which will assess people and direct them into care pathways which provide appropriate support, treatment, and rehabilitation.
To support clinical leadership in this area, NHS England worked in partnership with the British Society of Physical and Rehabilitation Medicine to establish the International Post- Covid and Post-Infection Conditions Society to facilitate the ongoing sharing of best practice to support people affected by long COVID-19.
Ongoing projects funded through the National Institute of Health and Care Research (NIHR) and Medical Research Council (MRC) aim to improve our understanding of the diagnosis and underlying mechanisms of long COVID-19 and the effectiveness of both pharmacological and non-pharmacological therapies and interventions, as well as to evaluate clinical care. The NIHR welcomes funding applications for research into any aspect of human health, including long COVID-19. The NIHR and MRC remain committed to funding high-quality research to understand the causes, consequences, and treatment of post-viral conditions, including long COVID-19, and are actively exploring next steps for research into post-viral conditions.
On 6 November 2025, the NIHR and MRC hosted a showcase event for post-acute infection conditions, including long COVID-19, research. This brought together people with lived experience, researchers, clinicians, and research funders to help stimulate further research in this field. We are now considering discussions from the showcase event to explore next steps to stimulate further vital research in this area.
We are determined to accelerate progress in the treatment and management of long COVID-19. This includes a new funding opportunity for a development award which is focussed on the feasibility of a phase 2 platform clinical trial that tests multiple repurposed pharmaceutical interventions and/or non-pharmacological interventions and devices. This targeted funding opportunity is one component of our approach to improve evidence around the diagnosis, management, and treatment of post-acute infection conditions, including long COVID-19.
Asked by: Roz Savage (Liberal Democrat - South Cotswolds)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether he has made an assessment of the potential impact of the closure of dedicated Long Covid services on patient outcomes; and what steps he is taking to ensure that the long-term effects of Covid-19 are (a) properly identified, (b) monitored and (c) treated.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
While no central assessment has been made of the impact of local closures of post-COVID-19 services on patient outcomes and data collection, the Government understands the scale of the issue at hand, particularly the impact of long COVID-19 on health, employment, and the economy.
The Government is aware that post-acute infection conditions, such as long COVID-19, can have a devastating effect on those who suffer from them. We are committed to taking a comprehensive and compassionate approach to supporting individuals with post-acute infection conditions such as long COVID-19, recognising the unique challenges these conditions present.
Integrated care boards are responsible for commissioning specialist services for long COVID-19 that meet the needs of their population, subject to local prioritisation and funding. NHS England has published commissioning guidance for post-COVID-19, or long COVID-19, services, which sets out a blueprint for best practice in supporting people with long COVID-19 and is designed to be adapted to local needs. This guidance is avaiable at the following link:
https://www.england.nhs.uk/publication/national-commissioning-guidance-for-post-covid-services/
Anyone who is concerned about long lasting symptoms after having COVID-19 should contact their general practitioner (GP). If appropriate, their GP will refer them to a National Health Service long COVID-19 service where available, or a suitable alternative, which will assess people and direct them into care pathways which provide appropriate support, treatment, and rehabilitation.
To support clinical leadership in this area, NHS England worked in partnership with the British Society of Physical and Rehabilitation Medicine to establish the International Post- Covid and Post-Infection Conditions Society to facilitate the ongoing sharing of best practice to support people affected by long COVID-19.
Ongoing projects funded through the National Institute of Health and Care Research (NIHR) and Medical Research Council (MRC) aim to improve our understanding of the diagnosis and underlying mechanisms of long COVID-19 and the effectiveness of both pharmacological and non-pharmacological therapies and interventions, as well as to evaluate clinical care. The NIHR welcomes funding applications for research into any aspect of human health, including long COVID-19. The NIHR and MRC remain committed to funding high-quality research to understand the causes, consequences, and treatment of post-viral conditions, including long COVID-19, and are actively exploring next steps for research into post-viral conditions.
On 6 November 2025, the NIHR and MRC hosted a showcase event for post-acute infection conditions, including long COVID-19, research. This brought together people with lived experience, researchers, clinicians, and research funders to help stimulate further research in this field. We are now considering discussions from the showcase event to explore next steps to stimulate further vital research in this area.
We are determined to accelerate progress in the treatment and management of long COVID-19. This includes a new funding opportunity for a development award which is focussed on the feasibility of a phase 2 platform clinical trial that tests multiple repurposed pharmaceutical interventions and/or non-pharmacological interventions and devices. This targeted funding opportunity is one component of our approach to improve evidence around the diagnosis, management, and treatment of post-acute infection conditions, including long COVID-19.
Asked by: Carla Lockhart (Democratic Unionist Party - Upper Bann)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what plans his Department has to encourage collaboration between NHS Trusts and pharmaceutical companies to enhance cancer clinical trials.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department is committed to ensuring that all patients, including those with cancer, have access to cutting-edge clinical trials and innovative, lifesaving treatments.
We are incentivising clinical trials and strengthening collaboration between pharmaceutical companies and National Health Service trusts by streamlining processes and cutting set‑up times to 150 days by March 2026, ensuring the United Kingdom offers a faster, more competitive environment for delivering high‑quality research.
The Department funded National Institute of Health and Care Research (NIHR) funds research and research infrastructure which supports patients and the public to participate in high-quality research. This includes Experimental Cancer Medicine Centres, co-funded by NIHR, Cancer Research UK, and the Little Princess Trust, which form a UK-wide network that brings together world leading laboratory and clinical researchers to deliver pioneering early phase cancer trials for adults and children. Additionally, the Medicines and Healthcare products Regulatory Agency will introduce a 14-day assessment route for phase 1 trials, adopting an innovative stepwise approach, restoring a rapid pathway for the earliest testing of new medicines in people, a key draw for global pharmaceutical companies deciding where to base their research.
NHS England is delivering specific collaborative initiatives with industry such as the Cancer Vaccine Launch Pad (CVLP). The NHS CVLP is a platform that is speeding up access to clinical trials for cancer vaccines and immunotherapies for patients who have been diagnosed with cancer. The CVLP platform is designed to be company and clinical trial agnostic. Different companies have been involved in the CVLP and trials in the CVLP portfolio have included cancers such as head and neck cancer melanoma and colorectal cancer.
35 Commercial Research Delivery Centres (CRDCs), including primary care been established largely within NHS trusts. CRDCs will expand capacity, streamline set-up, and give patients faster access to innovative treatments and clinical trials, including those concerning cancer.